Top 5 Stocks to Buy Now
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free CRSP Stock Alerts

CRISPR Therapeutics (CRSP) Competitors

CRISPR Therapeutics logo
$54.09 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$53.82 -0.27 (-0.50%)
As of 06/18/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

Should you buy CRISPR Therapeutics stock or one of its competitors? MarketBeat compares CRISPR Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CRISPR Therapeutics include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry.

How does CRISPR Therapeutics compare to Allogene Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

CRISPR Therapeutics presently has a consensus target price of $67.78, suggesting a potential upside of 25.31%. Allogene Therapeutics has a consensus target price of $8.52, suggesting a potential upside of 326.11%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.58
Allogene Therapeutics
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.69

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CRISPR Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

Allogene Therapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$3.51M1,486.32-$581.60M-$6.22N/A
Allogene Therapeutics$20K34,515.00-$190.89M-$0.77N/A

Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Allogene Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR Therapeutics-13,856.54% -25.66% -20.39%
Allogene Therapeutics N/A -56.45%-40.36%

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Allogene Therapeutics. MarketBeat recorded 3 mentions for CRISPR Therapeutics and 1 mentions for Allogene Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.80 beat Allogene Therapeutics' score of -1.74 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CRISPR Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Allogene Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Very Negative

Summary

Allogene Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Axsome Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

CRISPR Therapeutics presently has a consensus target price of $67.78, indicating a potential upside of 25.31%. Axsome Therapeutics has a consensus target price of $258.95, indicating a potential upside of 3.37%. Given CRISPR Therapeutics' higher possible upside, equities analysts clearly believe CRISPR Therapeutics is more favorable than Axsome Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.58
Axsome Therapeutics
1 Sell rating(s)
0 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.95

Axsome Therapeutics has a net margin of -26.59% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR Therapeutics-13,856.54% -25.66% -20.39%
Axsome Therapeutics -26.59%-267.16%-28.53%

In the previous week, Axsome Therapeutics had 16 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 19 mentions for Axsome Therapeutics and 3 mentions for CRISPR Therapeutics. Axsome Therapeutics' average media sentiment score of 1.18 beat CRISPR Therapeutics' score of 0.80 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CRISPR Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Axsome Therapeutics
10 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Axsome Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$3.51M1,486.32-$581.60M-$6.22N/A
Axsome Therapeutics$638.50M20.19-$183.17M-$3.73N/A

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CRISPR Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Summary

Axsome Therapeutics beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Beam Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market.

In the previous week, Beam Therapeutics had 4 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 3 mentions for CRISPR Therapeutics. Beam Therapeutics' average media sentiment score of 0.99 beat CRISPR Therapeutics' score of 0.80 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CRISPR Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Beam Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Beam Therapeutics has a net margin of -39.66% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Beam Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR Therapeutics-13,856.54% -25.66% -20.39%
Beam Therapeutics -39.66%-29.00%-22.61%

CRISPR Therapeutics currently has a consensus target price of $67.78, indicating a potential upside of 25.31%. Beam Therapeutics has a consensus target price of $46.83, indicating a potential upside of 37.18%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.58
Beam Therapeutics
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.71

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Beam Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$3.51M1,486.32-$581.60M-$6.22N/A
Beam Therapeutics$139.74M25.13-$79.99M-$0.68N/A

Summary

Beam Therapeutics beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Editas Medicine has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, CRISPR Therapeutics had 3 more articles in the media than Editas Medicine. MarketBeat recorded 3 mentions for CRISPR Therapeutics and 0 mentions for Editas Medicine. CRISPR Therapeutics' average media sentiment score of 0.80 beat Editas Medicine's score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Editas Medicine Neutral
CRISPR Therapeutics Positive

Editas Medicine has a net margin of -281.59% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Editas Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Editas Medicine-281.59% -677.39% -58.25%
CRISPR Therapeutics -13,856.54%-25.66%-20.39%

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$40.52M6.50-$160.06M-$1.23N/A
CRISPR Therapeutics$3.51M1,486.32-$581.60M-$6.22N/A

Editas Medicine presently has a consensus price target of $5.40, suggesting a potential upside of 100.74%. CRISPR Therapeutics has a consensus price target of $67.78, suggesting a potential upside of 25.31%. Given Editas Medicine's higher probable upside, equities analysts clearly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Editas Medicine
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
CRISPR Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.58

Summary

CRISPR Therapeutics beats Editas Medicine on 9 of the 17 factors compared between the two stocks.

How does CRISPR Therapeutics compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

KALA BIO has a beta of -2.4, suggesting that its share price is 340% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market.

24.6% of KALA BIO shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 2.2% of KALA BIO shares are held by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

KALA BIO has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KALA BION/AN/A-$26.98M-$96.14N/A
CRISPR Therapeutics$3.51M1,486.32-$581.60M-$6.22N/A

In the previous week, CRISPR Therapeutics had 3 more articles in the media than KALA BIO. MarketBeat recorded 3 mentions for CRISPR Therapeutics and 0 mentions for KALA BIO. CRISPR Therapeutics' average media sentiment score of 0.80 beat KALA BIO's score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
KALA BIO Neutral
CRISPR Therapeutics Positive

KALA BIO presently has a consensus target price of $1,018.75, indicating a potential upside of 28,120.22%. CRISPR Therapeutics has a consensus target price of $67.78, indicating a potential upside of 25.31%. Given KALA BIO's higher probable upside, equities analysts clearly believe KALA BIO is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KALA BIO
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
CRISPR Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.58

KALA BIO has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
KALA BION/A -1,336.10% -94.85%
CRISPR Therapeutics -13,856.54%-25.66%-20.39%

Summary

CRISPR Therapeutics beats KALA BIO on 12 of the 16 factors compared between the two stocks.

Get CRISPR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRSP vs. The Competition

Export
MetricCRISPR TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.22B$3.41B$6.43B$12.59B
Dividend YieldN/A2.32%2.68%5.81%
P/E Ratio-8.7019.7324.7524.43
Price / Sales1,486.32320.08529.99108.89
Price / CashN/A127.8445.0755.09
Price / Book2.688.1610.806.58
Net Income-$581.60M$23.94M$3.57B$337.17M
7 Day Performance8.61%2.57%0.72%0.83%
1 Month Performance8.40%0.69%0.41%2.25%
1 Year Performance22.24%55.09%29.34%36.14%

CRISPR Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRSP
CRISPR Therapeutics
3.5178 of 5 stars		$54.09
flat		$67.78
+25.3%		+22.2%$5.22B$3.51MN/A460
ALLO
Allogene Therapeutics
2.3935 of 5 stars		$1.85
-1.6%		$8.52
+360.7%		+62.6%$638.54MN/AN/A310
AXSM
Axsome Therapeutics
2.2693 of 5 stars		$235.14
+1.2%		$251.26
+6.9%		+148.8%$12.10B$708.24MN/A380
BEAM
Beam Therapeutics
3.2734 of 5 stars		$29.78
+1.3%		$46.83
+57.3%		+103.7%$3.06B$164.01MN/A510
EDIT
Editas Medicine
2.6374 of 5 stars		$2.64
-2.6%		$5.40
+104.5%		+21.2%$258.47M$38.69MN/A230

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CRSP) was last updated on 6/21/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
A huge SpaceX error just led one stock to 3X move!
SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker....
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel